Published in J Nucl Med on November 15, 2012
Neuromodulation by acetylcholine: examples from schizophrenia and depression. Curr Opin Neurobiol (2014) 0.90
Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry (2013) 0.86
In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry (2014) 0.83
PET imaging of acetylcholinesterase inhibitor-induced effects on α4β2 nicotinic acetylcholine receptor binding. Synapse (2013) 0.82
High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness. Psychopharmacology (Berl) (2013) 0.80
Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology (2015) 0.80
Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand 18F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys. Synapse (2014) 0.77
Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology (Berl) (2015) 0.76
Evaluation of the Nicotinic Acetylcholine Receptor-Associated Proteome at Baseline and Following Nicotine Exposure in Human and Mouse Cortex. eNeuro (2016) 0.76
Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. Neuroimage (2016) 0.75
CHRNA4 and ANKK1 Polymorphisms Influence Smoking-Induced Nicotinic Acetylcholine Receptor Upregulation. Nicotine Tob Res (2016) 0.75
An inventory for measuring depression. Arch Gen Psychiatry (1961) 84.61
5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol (2000) 1.67
Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol (2008) 1.39
Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem (1996) 1.33
123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med (2005) 1.14
Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med (2010) 1.10
Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry (2012) 1.07
Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging (2002) 1.03
Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse (2003) 1.00
Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry (2012) 0.97
Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. J Nucl Med (2000) 0.92
In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. Life Sci (1998) 0.90
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol (2010) 0.89
In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport (1998) 0.89
Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem (2008) 0.88
Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys. Synapse (2005) 0.88
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest (2006) 3.81
Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab (2003) 3.77
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther (2004) 3.49
Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21
Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry (2007) 2.90
Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med (2003) 2.71
Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci (2002) 2.69
Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab (2002) 2.58
Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry (2005) 2.45
Nicotine decreases food intake through activation of POMC neurons. Science (2011) 2.41
Sex and estrogen influence drug abuse. Trends Pharmacol Sci (2004) 2.41
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab (2002) 2.38
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics (2004) 2.37
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci (2002) 2.32
Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry (2009) 2.25
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology (2004) 2.24
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron (2002) 2.21
Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry (2010) 2.19
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage (2010) 2.18
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med (2012) 2.16
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry (2006) 2.07
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Species-specific calls evoke asymmetric activity in the monkey's temporal poles. Nature (2004) 2.04
Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci (2006) 1.99
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst (2011) 1.97
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther (2005) 1.96
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A (2013) 1.95
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics (2006) 1.83
11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. J Nucl Med (2005) 1.81
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab (2009) 1.80
Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med (2010) 1.75
Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry (2005) 1.75
Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology (2003) 1.74
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry (2004) 1.71
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci (2010) 1.71
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) 1.63
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J Neurochem (2003) 1.60
Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol (2010) 1.59
Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse (2006) 1.59
Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev (2011) 1.57
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics (2007) 1.56
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol (2012) 1.52
Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev (2004) 1.51
Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry (2010) 1.50
High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry (2004) 1.49
Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol (2007) 1.49
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry (2007) 1.48
Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos (2002) 1.47
Chest radiograph as a triage tool in the imaging-based diagnosis of pulmonary embolism. AJR Am J Roentgenol (2005) 1.46
The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. Neuron (2006) 1.46
Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons. J Clin Invest (2007) 1.45
Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol (2007) 1.44
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry (2010) 1.44
Does gamma-hydroxybutyrate (GHB) have a role in the treatment of alcoholism? Alcohol Alcohol (2010) 1.43
Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone. J Psychopharmacol (2010) 1.43
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics (2005) 1.43
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat (2008) 1.42
Caffeine dependence in teenagers. Drug Alcohol Depend (2002) 1.42
beta2-Subunit-containing nicotinic acetylcholine receptors are involved in nicotine-induced increases in conditioned reinforcement but not progressive ratio responding for food in C57BL/6 mice. Psychopharmacology (Berl) (2005) 1.38
An instructive role for patterned spontaneous retinal activity in mouse visual map development. Neuron (2011) 1.38
Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse (2009) 1.38
Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) (2010) 1.37
An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res (2007) 1.37
Molecular genetics of nicotine metabolism. Handb Exp Pharmacol (2009) 1.36
Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab (2011) 1.36
Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry (2002) 1.35
Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med (2004) 1.35
Prenatal and adolescent exposure to tobacco smoke modulates the development of white matter microstructure. J Neurosci (2007) 1.35
Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev (2012) 1.34
The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. Nat Neurosci (2012) 1.33
CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.33
Selective frontal, parietal, and temporal networks in generalized seizures. Neuroimage (2003) 1.33
Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med (2008) 1.32
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics (2009) 1.28
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci (2011) 1.28
Toward an evolutionary perspective on conceptual representation: species-specific calls activate visual and affective processing systems in the macaque. Proc Natl Acad Sci U S A (2004) 1.27